版本:
中国

BRIEF-Novo Nordisk: FDA approves label update for obesity drug Saxenda

April 27 Danish drug maker Novo Nordisk A/S says:

* Receives approval of Saxenda (liraglutide) injection 3 mg label update including long-term safety and efficacy data from 3-year trial from U.S. Food and Drug Administration

* "We are pleased by the FDA's approval, which marks Saxenda as the only weight-loss and management medicine in a pen supported by long-term safety and efficacy data," says Dr. Todd Hobbs, vice president and chief medical officer at Novo Nordisk U.S.

* For more on the data: Further company coverage: (Reporting by Stine Jacobsen)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐